Wall Street Zen Downgrades Emergent Biosolutions (NYSE:EBS) to Buy

Emergent Biosolutions (NYSE:EBS) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

A number of other research firms also recently commented on EBS. Weiss Ratings reiterated a “hold (c-)” rating on shares of Emergent Biosolutions in a report on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Emergent Biosolutions in a research note on Tuesday, December 16th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $15.00.

Emergent Biosolutions Stock Performance

Shares of Emergent Biosolutions stock opened at $8.19 on Friday. The business has a 50-day simple moving average of $11.68 and a 200-day simple moving average of $10.40. The company has a debt-to-equity ratio of 1.14, a quick ratio of 3.15 and a current ratio of 5.76. Emergent Biosolutions has a one year low of $4.02 and a one year high of $14.06. The company has a market cap of $429.98 million, a PE ratio of 9.75 and a beta of 2.35.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.54). Emergent Biosolutions had a return on equity of 15.62% and a net margin of 7.08%.The firm had revenue of $148.70 million during the quarter, compared to analysts’ expectations of $217.50 million. On average, equities research analysts forecast that Emergent Biosolutions will post -0.63 EPS for the current fiscal year.

Insider Activity at Emergent Biosolutions

In other news, Director Ronald Richard sold 21,984 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $11.97, for a total value of $263,148.48. Following the completion of the sale, the director directly owned 98,417 shares of the company’s stock, valued at approximately $1,178,051.49. This represents a 18.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.20% of the company’s stock.

Institutional Trading of Emergent Biosolutions

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Torren Management LLC purchased a new position in shares of Emergent Biosolutions in the 4th quarter valued at approximately $37,000. CANADA LIFE ASSURANCE Co acquired a new stake in shares of Emergent Biosolutions during the fourth quarter worth $45,000. Legal & General Group Plc purchased a new position in Emergent Biosolutions in the 2nd quarter valued at $31,000. Ameritas Investment Partners Inc. purchased a new position in Emergent Biosolutions in the 2nd quarter valued at $35,000. Finally, Farther Finance Advisors LLC increased its stake in Emergent Biosolutions by 361.3% in the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 4,827 shares during the period. 78.40% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Won multiyear Canadian contracts worth up to ~CAD 140 million, including >CAD 35M in orders expected in 2026, which adds near-term funded backlog and visibility for future revenue. Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada
• Positive Sentiment: Board authorized a new $50 million stock repurchase program (replacing the prior authorization); buybacks can support the share price and signal confidence from management. Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
• Positive Sentiment: Company highlights a return to profitability and ongoing turnaround progress, which could improve investor sentiment if execution continues. Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround
• Neutral Sentiment: Full Q4 prepared remarks, slide deck and presentation materials were filed — useful for digging into segment trends, contract timing and margin details but not a near-term catalyst by itself. Earnings Call Prepared Remarks Transcript Q4 Results – Earnings Call Presentation
• Neutral Sentiment: Local coverage and snapshots summarize the quarter and management commentary; useful background for investors reviewing call takeaways. Emergent Biosolutions: Q4 Earnings Snapshot
• Negative Sentiment: Q4 results missed expectations: EPS of ($0.43) vs. consensus $0.11 and revenue $148.7M vs. est. $217.5M — a clear earnings and top-line shortfall that weighed on the stock. Earnings Call Highlights: Strategic Gains Amid Revenue …
• Negative Sentiment: FY‑2026 revenue guidance was reset much lower to ~$720M–$760M versus street expectations near $1.2B; EPS guidance was not clearly reiterated in the release — the weak outlook is the primary driver of the share decline. Earnings Call Highlights: Strategic Gains Amid Revenue …

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.